Delayed lupus onset in (NZB × NZW)F1 mice expressing a human C-reactive protein transgene

Arthritis and Rheumatism

Volumn 48, Issue 6, 2003, Pages 1602-1611

  Szalai, Alexander J ^a,b,d   Weaver, Casey T ^a,b   McCrory, Mark A ^a,b   Van Ginkel, Frederik W ^a,b   Reiman, Rachael M ^a,b   Kearney, John F ^a,b   Marion, Tony N ^c   Volanakis, John E ^a,b  

^a BIOMEDICAL SCIENCES RESEARCH CENTER ALEXANDER FLEMING   (Greece)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^d University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; COMPLEMENT COMPONENT C3; DNA ANTIBODY; DOUBLE STRANDED DNA; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M;

AGE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL FUSION; CELL PROLIFERATION; CELL PROTECTION; CELL ULTRASTRUCTURE; CHROMATIN CONDENSATION; CONTROLLED STUDY; CRP TRANSGENE; DISEASE COURSE; DISEASE PREDISPOSITION; DNA DETERMINATION; ELECTRON MICROSCOPY; ENZYME LINKED IMMUNOSORBENT ASSAY; GLOMERULUS; GLOMERULUS BASEMENT MEMBRANE; HUMAN; IMMUNE COMPLEX DISEASE; IMMUNOFLUORESCENCE MICROSCOPY; IMMUNOGLOBULIN DEPOSITION; IMMUNOGLOBULIN PRODUCTION; IN SITU HYBRIDIZATION; KIDNEY CORTEX; KIDNEY PARENCHYMA; LUPUS ERYTHEMATOSUS; MESANGIUM CELL; MORTALITY; MOUSE; NONHUMAN; PATHOGENESIS; PODOCYTE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEINURIA; RNA ANALYSIS; STATISTICAL SIGNIFICANCE; SURVIVAL TIME; TRANSGENE;

ANIMALS; ANTIBODIES, ANTINUCLEAR; C-REACTIVE PROTEIN; CAPILLARIES; COMPLEMENT C3; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; KIDNEY GLOMERULUS; LONGEVITY; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; MICE, INBRED C57BL; MICE, INBRED NZB; MICE, TRANSGENIC; TRANSGENES;

EID: 0038798080     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.11026     Document Type: Article

References (49)

1. Wallace DJ, Metzger AL. Systemic lupus erythematosus: clinical aspects and treatment. In: Koopman WJ, editor. Arthritis and allied conditions: a textbook of rheumatology. 13th ed. Baltimore: Williams & Wilkins; 1997. p. 1319-45.
2. Zimmerman R, Radhakrishnan J, Valeri A, Appel G. Advances in the treatment of lupus nephritis. Annu Rev Med 2001;52:63-78.
3. Helyer BJ, Howie JB. Renal disease associated with positive lupus erythematosus tests in a cross-bred strain of mice. Nature 1963; 4863:197.
4. Theofilopoulos AN, Dixon FJ. Experimental murine systemic lupus erythematosus. In: Swanson J, Chengerman K, editors. Animal models of disease. Washington (DC): US Department of Agriculture; 1989. p. 121-202.
5. Vyse TJ, Kotzin BL. Genetic susceptibility to systemic lupus erythematosus. Ann Rev Immunol 1998;16:261-92.
6. Ballou SP, Kushner I. C-reactive protein and the acute phase response. Adv Intern Med 1992;37:313-36.
7. Gabay C, Roux-Lombard P, de Moerloose P, Dayer J-M, Wischer T, Guerne PA. Absence of correlation between interleukin-6 and C-reactive protein blood levels in systemic lupus erythematosus compared with rheumatoid arthritis. J Rheumatol 1993;20:815-21.
8. Pepys MB, Lanham JG, De Beer FC. C-reactive protein in SLE. Clin Rheum Dis 1982;8:91-103.
9. Pereira DA, Silva JA, Elkon KB, Hughes GRV, Dyck RF, Pepys MB. C-reactive protein levels in systemic lupus erythematosus: a classification criterion? Arthritis Rheum 1980;23:770-1.
10. Du Clos TW, Zlock LT, Rubin RL. Analysis of the binding of C-reactive protein to histones and chromatin. J Immunol 1988; 141:4266-70.
11. Minota S, Morino N, Sakurai H, Yamada A, Yazaki Y. Interrelationship between autoepitope, DNA-binding domain, and CRP-binding domain on a histone H1 molecule. Clin Immunol Immunopathol 1993;66:269-71.
12. Du Clos TW. C-reactive protein reacts with the U1 small nuclear ribonucleoprotein. J Immunol 1989;143:2553-9.
13. Robey FA, Jones KD, Steinberg AD. C-reactive protein mediates the solubilization of nuclear DNA by complement in vitro. J Exp Med 1985;161:1344-56.
14. Kaplan MH, Volanakis JE. Interaction of C-reactive protein complexes with the complement system. I. Consumption of human complement associated with the reaction of C-reactive protein with pneumococcal C-polysaccharide and with the choline phosphatides, lecithin and sphingomyelin. J Immunol 1974;112:2135-47.
15. Marnell LL, Mold C, Volzer MA, Burlingame RW, Du Clos TW. C-reactive protein binds to FcγRI in transfected COS cells. J Immunol 1995;55:2185-93.
16. Bharadwaj D, Stein MP, Volzer M, Mold C, Du Clos TW. The major receptor for C-reactive protein on leukocytes is FcγRII. J Exp Med 1999;190:585-90.
17. Stein MP, Mold C, Du Clos TW. C-reactive protein binding to murine leukocytes requires Fcγ receptors. J Immunol 2000;164:1514-20.
18. Gershov D, Kim S, Brot N, Elkon KB. C-reactive protein binds to apoptotic cells, protects the cells from assembly of the terminal complement components, and sustains an antiinflammatory innate immune response: implications for systemic autoimmunity. J Exp Med 2000;192:1353-63.
19. Bodmer B, Siboo R. Isolation of mouse C-reactive protein from liver and serum. J Immunol 1977;118:1086-9.
20. Burlingame RW, Volzer MA, Harris J, Du Clos TW. The effects of acute phase proteins on clearance of chromatin from the circulation of normal mice. J Immunol 1996;156:4783-8.
21. 1 mice treated with C-reactive protein. Clin Immunol Immunopathol 1994;70:22-7.
22. Szalai AJ, Briles DE, Volanakis JE. Human C-reactive protein is protective against fatal Streptococcus pneumoniae infection in transgenic mice. J Immunol 1995;155:2557-63.
23. Ciliberto G, Arcone R, Wagner EF, Rüther U. Inducible and tissue-specific expression of human C-reactive protein in transgenic mice. EMBO J 1987;6:4017-22.
24. Szalai AJ, van Ginkel FW, Dalrymple SA, Murray R, McGhee JR, Volanakis JE. Testosterone and IL-6 requirements for human C-reactive protein gene expression in transgenic mice. J Immunol 1998;160:5294-9.
25. Jacob CO, Hwang F. Definition of microsatellite size variants for Tnfa and Hsp70 in autoimmune and nonautoimmune mouse strains. Immunogenetics 1992;36:182-8.
26. 1 mice are clonally heterogeneous, but the majority share a common idiotype. J Immunol 1982;128:668-74.
27. Kilpatrick JM, Kearney JF, Volanakis JE. Demonstration of calcium-induced conformational change(s) in C-reactive protein by using monoclonal antibodies. Mol Immunol 1982;19:1159-65.
28. Volanakis JE, Xu Y, Macon KJ. Human C-reactive protein and host defense. In: Marchalonis JJ, Reinish CL, editors. Defense molecules. New York: Alan R. Liss; 1990. p. 161-75.
29. 1 hybrid mice. Clin Exp Immunol 1976;26:363-70.
30. Klein L, Klein T, Rüther U, Kyewski B. CD4 T cell tolerance to human C-reactive protein, an inducible serum protein, is mediated by medullary thymic epithelium. J Exp Med 1998;188:5-16.
31. Laiho K, Tiitinen S, Teppo A-M, Kauppi M, Kaarela K. Serum C-reactive protein is rarely lost into urine in patients with secondary amyloidosis and proteinuria. Clin Rheumatol 1998;17:234-5.
32. Nakahara C, Kanemoto K, Saito N, Oyake Y, Kamoda T, Nagata M, et al. C-reactive protein frequently localizes in the kidney in glomerular disease. Clin Nephrol 2001;55:365-70.
33. Passwell J, Schreiner GF, Nonaka M, Beuscher HU, Colten HR. Local extrahepatic expression of complement genes C3, factor B, C2, and C4 is increased in murine lupus nephritis. J Clin Invest 1988;82:1676-84.
34. 1) mouse strains. Immunology 1990;71:290-4.
35. Ault BH, Colten HR. Cellular specificity of murine renal C3 expression in two models of inflammation. Immunology 1994;81:655-60.
36. Takahashi M, Takahashi S, Brade V, Nussenzweig V. Requirements for the solubilization of immune aggregates by complement: the role of the classical pathway. J Clin Invest 1978;62:349-58.
37. Mold C, Kingzette M, Gewurz H. C-reactive protein inhibits pneumococcal activation of the alternative pathway by increasing the interaction between factor H and C3b. J Immunol 1984;133:882-5.
38. Schifferli JA, Woo P, Peters DK. Complement-mediated inhibition of immune precipitation. I. Role of the classical and alternative pathways. Clin Exp Immunol 1982;47:555-62.
39. Watanabe H, Garnier G, Circolo A, Wetsel RA, Ruiz P, Holers VM, et al. Modulation of renal disease in MRL/lpr mice genetically deficient in the alternative pathway factor B. J Immunol 2000;164:786-94.
40. Clynes R, Dumitru C, Ravetch JV. Uncoupling of immune complex formation and kidney damage in autoimmune glomerulonephritis. Science 1998;279:1052-4.
41. Van den Dobbelsteen MEA, van der Woude FJ, Schroeijers WEM, Klar-Mohamad N, van Es LA, Daha MR. Both IgG- and C1q-receptors play a role in the enhanced binding of IgG complexes to human mesangial cells. J Am Soc Nephrol 1996;7:573-81.
42. Sterzel RB, Rupprecht HD. Glomerular mesangial cells. In: Neilson EG, Couser WG, editors. Immunologic renal diseases. Philadelphia: Lippincott-Raven; 1997. p. 595-626.
43. Yamada Y, Kimball K, Okusawa S, Vachino G, Margolis N, Sohn JW, et al. Cytokines, acute phase proteins, and tissue injury: C-reactive protein opsonizes dead cells for debridement and stimulates cytokine production. Ann N Y Acad Sci 1990;587:351-61.
44. Gewurz H, Zhang X-H, Lint TF. Structure and function of the pentraxins. Curr Opin Immunol 1995;7:54-64.
45. Bickerstaff MCM, Botto M, Hutchinson WL, Herbert J, Tennent GA, Bybee A, et al. Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity. Nat Med 1999;5:694-7.
46. Butler PJG, Tennent GA, Pepys MB. Pentraxin-chromatin interactions: serum amyloid P component specifically displaces H1-type histones and solubilizes native long chromatin. J Exp Med 1990; 172:152-7.
47. Hintner H, Booker J, Ashworth J, Aubock J, Pepys MB, Breathnach SM. Amyloid P component binds to keratin bodies in human skin and to isolated keratin filament aggregates in vitro. J Invest Dermatol 1988;91:22-8.
48. Breathnach SM, Kofler H, Sepp N, Ashworth J, Woodrow D, Pepys MB, et al. Serum amyloid P component binds to cell nuclei in vitro and to in vivo deposits of extracellular chromatin in systemic lupus erythematosus. J Exp Med 1989;170:1433-8.
49. Szalai AJ. The antimicrobial activity of C-reactive protein. Microb Infect 2002;4:201-5.